TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31666068

Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements in healthy subgroup
Number of subjects: 575

Group type: COMPARATOR
Intervention: Echocardiographic measurements in general population
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: M-mode derived LV measurements
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Right ventricle basal dimension
Number of subjects: 575
Study: 29020174

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3949

Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy
Number of subjects: 3949
Study: 26194691

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin + Oral contraceptives (OC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 23592752

Group type: EXPERIMENTAL
Intervention: 3.4 g/d EPA + DHA supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.85 g/d EPA + DHA supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21916639

Group type: EXPERIMENTAL
Intervention: T12PR24 (telaprevir for 12 weeks, peginterferon-ribavirin for 24 weeks)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: T12PR48 (telaprevir for 12 weeks, peginterferon-ribavirin for 48 weeks)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 540
Study: 19567451

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 306

Group type: COMPARATOR
Intervention: LV5FUs
Number of subjects: 306
Study: 17100745

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional gold alloy frameworks
Number of subjects: 155
Study: 15289960

Group type: EXPERIMENTAL
Intervention: UDCA (8-10 mg/kg per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11786598

Group type: EXPERIMENTAL
Intervention: Healthy Habits (HH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Typical Care (TC)
Number of subjects: 44
Study: 9675655

Group type: EXPERIMENTAL
Intervention: Natural beta interferon 3,000,000 international units intramuscularly three times a week for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Symptomatic drugs (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Natural beta interferon
Number of subjects: 40
Study: 8088691

Group type: EXPERIMENTAL
Intervention: nilvadipine 8 mg (mornings) and placebo (evenings)
Number of subjects: 61

Group type: COMPARATOR
Intervention: slow‐release nifedipine 20 mg b.i.d.
Number of subjects: 61
Study: 2654201

Group type: EXPERIMENTAL
Intervention: Computer-based instructional system in pharmacokinetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional teaching in clinical pharmacokinetics
Number of subjects: 0
Study: 1101616

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etidocaine 0.375%
Number of subjects: 0
Study: 6104497

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg ml-1 i.v. (average dose 0.014 mg kg-1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Diazepam 5 mg ml-1 i.v. (0.29 mg kg-1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 82

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 82
Study: 31619429

Group type: EXPERIMENTAL
Intervention: Healthy lifestyles program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparator arm
Number of subjects: 30
Study: 29074420

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 26844764

Group type: EXPERIMENTAL
Intervention: Baseline serum albumin levels (mean 3.5 ± 0.5 g/dL)
Number of subjects: 456
Study: 24637284

Group type: EXPERIMENTAL
Intervention: Sexuality education coaching program (10 sessions over 3 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group received 2 sessions of sexuality education (including physiology and sexual abuse prevention)
Number of subjects: 44
Study: 21262935

Group type: EXPERIMENTAL
Intervention: Transbond XT (etch-and-rinse adhesive) with torsion load
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transbond XT (etch-and-rinse adhesive) without torsion load
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transbond Plus (self-etching primer adhesive) with torsion load
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transbond Plus (self-etching primer adhesive) without torsion load
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beauty Ortho Bond (self-etching primer adhesive) with torsion load
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beauty Ortho Bond (self-etching primer adhesive) without torsion load
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Torsion load (1.45 N/cm) applied
Number of subjects: 60

Group type: COMPARATOR
Intervention: No torsion load applied
Number of subjects: 60
Study: 19175870

Group type: EXPERIMENTAL
Intervention: HCV FibroSURE
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: FIBROSpect II
Number of subjects: 95
Study: 17717768

Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 35
Study: 12944341

Group type: EXPERIMENTAL
Intervention: Aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 262

Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 262
Study: 10870361

Group type: EXPERIMENTAL
Intervention: Low doses of racemic ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study: 9369422

Group type: EXPERIMENTAL
Intervention: BCR/ABL-positive patients (n=23, 22% of total)
Number of subjects: 144

Group type: COMPARATOR
Intervention: BCR/ABL-negative patients
Number of subjects: 144
Study: 8239585

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3519236

Group type: EXPERIMENTAL
Intervention: Disopyramide capsules (600 mg per day, q.i.d.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Disopyramide slow release tablets (600 mg per day, b.i.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28850429

Group type: EXPERIMENTAL
Intervention: Physical therapy or manual therapy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 181
Study: 25239466

Group type: EXPERIMENTAL
Intervention: Nevirapine at 200 mg twice daily
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Efavirenz at 600 mg daily
Number of subjects: 526
Study: 23230122

Group type: EXPERIMENTAL
Intervention: PDEOC-10 diet (10% by-product)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDEOC-20 diet (20% by-product)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control diet (PDEOC-0, without olive by-product)
Number of subjects: 60
Study: 21712242

Group type: COMPARATOR
Intervention: Rifabutin 150 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg with atazanavir 300 mg/ritonavir 100 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg three times weekly with atazanavir/ritonavir
Number of subjects: 33
Study: 19584189

Group type: COMPARATOR
Intervention: 1 mg estradiol combined with 2.5 mg medroxyprogesterone
Number of subjects: 11

Group type: COMPARATOR
Intervention: 5 mg/d oral risedronate (Actonel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: soy isoflavones from cotyledon
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: soy isoflavones from germ
Number of subjects: 11
Study: 17722825

Group type: EXPERIMENTAL
Intervention: Penetration needling combined with electroacupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture combined with electroacupuncture
Number of subjects: 80
Study: 14506078

Group type: EXPERIMENTAL
Intervention: Octreotide (Sandostatin LAR)
Number of subjects: 7
Study: 11421500

Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae (M. vaccae)
Number of subjects: 337
Study: 9394204

Group type: EXPERIMENTAL
Intervention: Interactive training methods in STD management at one health center.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no training in STD management).
Number of subjects: 400
Study: 7967425

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (IST) using anti-lymphocyte globulin (ALG), cyclosporin A (CSA), and G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) from HLA-identical sibling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning for BMT using ALG and cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardisation and improvement of supportive therapy
Number of subjects: 0
Study: 2890791

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% ophthalmic solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30388045

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab followed by irinotecan at first progression (arm A)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Fluoropyrimidine plus irinotecan plus bevacizumab (arm B)
Number of subjects: 421
Study: 28395753

Group type: EXPERIMENTAL
Intervention: Selamectin/sarolaner spot-on formulation (6.0 mg selamectin and 1.0 mg sarolaner per kg bodyweight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selamectin/sarolaner spot-on formulation
Number of subjects: 30
Study: 25792808

Group type: EXPERIMENTAL
Intervention: BP-C1 treatment (daily intramuscular injections for 32 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BP-C1 treatment
Number of subjects: 47
Study: 23327861

Group type: EXPERIMENTAL
Intervention: Olopatadine 5 mg orally twice a day for 14 days
Number of subjects: 174

Group type: COMPARATOR
Intervention: Cetirizine 10 mg orally once a day for 14 days
Number of subjects: 174
Study: 21335259

Group type: EXPERIMENTAL
Intervention: High nicotine dependence
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Demographic and contextual variables (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, number of supportive others)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1504
Study: 19120329

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Emollient
Number of subjects: 45
Study: 17084257

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diet management
Number of subjects: 43
Study: 15082464

Group type: EXPERIMENTAL
Intervention: Extended Psychosocial Intervention (EPI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal Psychosocial Intervention (MPI)
Number of subjects: 70
Study: 11723153

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of hydroxycobalamin for 5 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 16
Study: 9741608

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 0800 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 1200 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 1600 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 2000 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pre‐ and postexercise rectal temperature
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postexercise blood pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma levels of testosterone and cortisol pre‐ and postexercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise‐induced responses of testosterone and cortisol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of testosterone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Testosterone to cortisol ratios
Number of subjects: 10
Study: 7528534

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a, 3 million IU subcutaneously three times a week
Number of subjects: 43

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 43
Study: 3132853

Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex HN) delivered through a needle catheter jejunostomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard 5% dextrose and electrolyte solutions
Number of subjects: 60
Study: 29997147

Group type: EXPERIMENTAL
Intervention: Postdilatation (postD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No postdilatation (control)
Number of subjects: 124
Study: 28625456

Group type: EXPERIMENTAL
Intervention: ondansetron HCl (8mg, 2ml IV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline (2ml IV)
Number of subjects: 120
Study: 25083773

Group type: EXPERIMENTAL
Intervention: Soft coagulation (Group S)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Heater probe thermocoagulation (Group H)
Number of subjects: 111
Study: 22990216

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced exposure from heavy to light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 0
Study: 21679528

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder) for 8 weeks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 4 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 20175801

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg co-administered with halofantrine 500 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Halofantrine 500 mg alone
Number of subjects: 15
Study: 17107392

Group type: EXPERIMENTAL
Intervention: Patient-rated severity score
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Physician-rated severity score
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Burden of disease questionnaire (DLQI)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Change over time in DLQI items
Number of subjects: 158
Study: 15589390

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11194517

Group type: COMPARATOR
Intervention: Infusion warmer and standard O.R. draping with two layers of cotton drapes (Group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Infusion warmer and reflecting disposable insulation (Thermadrape) (Group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infusion warmer and convective air warming with upper body blanket (Group 3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infusion warmer, convective air warming and reflecting disposable insulation (Group 4)
Number of subjects: 36
Study: 10345408

Group type: EXPERIMENTAL
Intervention: Expanded community-based services and case management
Number of subjects: 5254

Group type: COMPARATOR
Intervention: Control group (no expanded services)
Number of subjects: 5254
Study: 1889718

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7120220

Group type: EXPERIMENTAL
Intervention: Routine antepartum biophysical screening
Number of subjects: 692
Study: 31155698

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no MOPs)
Number of subjects: 18
Study: 28846877

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CII) of enoxaparin 40mg over 24h for three consecutive days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subcutaneous bolus (SCB) administration of enoxaparin 40mg once daily
Number of subjects: 39
Study: 27308826

Group type: EXPERIMENTAL
Intervention: Tyloxapol 1% (5 ml inhaled three times daily for 3 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline 0.9% (5 ml inhaled three times daily for 3 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tyloxapol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tyloxapol and Saline
Number of subjects: 19
Study: 23549519

Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1381
Study: 22124067

Group type: EXPERIMENTAL
Intervention: Cast metal crown resembling original tooth
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cast metal crown confirmed to ideal contours
Number of subjects: 40
Study: 19349629

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy supplemented with up to 6 counseling calls (high‐intensity disease management)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy supplemented with up to 2 counseling calls (moderate‐intensity disease management)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Combined disease management (both moderate and high intensity)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: High‐intensity disease management vs. moderate‐intensity disease management
Number of subjects: 750
Study: 16399190

Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 300

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 300
Study: 15290737

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg/week
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11386927

Group type: EXPERIMENTAL
Intervention: ramipril, 2.5 to 10 mg/d
Number of subjects: 1094

Group type: COMPARATOR
Intervention: amlodipine, 5 to 10 mg/d
Number of subjects: 1094
Study: 9731994

Group type: EXPERIMENTAL
Intervention: RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: RBC 400 mg BID for 4 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: COMPARATOR
Intervention: CLR 500 mg TID for the first 2 weeks
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Patients eradicated of H. pylori infection
Number of subjects: 203

Group type: COMPARATOR
Intervention: Patients who remained infected with H. pylori
Number of subjects: 203
Study: 7837160

Group type: EXPERIMENTAL
Intervention: ICT etidronate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison group (no etidronate treatment)
Number of subjects: 68
Study: 3422694

Group type: EXPERIMENTAL
Intervention: Slow intravenous infusion of epirubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus injection of epirubicin
Number of subjects: 0
Study: 29281033

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day and Aripiprazole 15 mg/day (combined)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26675056

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (Novasure®)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Balloon endometrial ablation (Thermablate®)
Number of subjects: 104
Study: 25352640

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg three times daily for 2 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23690551

Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 19876587

Group type: EXPERIMENTAL
Intervention: Camostat mesilate 200 mg three times daily for 2 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (1 or no findings)
Number of subjects: 95
Study: 18373286

Group type: EXPERIMENTAL
Intervention: C5: 2 x 5-g doses of creatine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: C10: 1 x 10-g dose of creatine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 59
Study: 17240614

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Racemic albuterol 2.5 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 15490770

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 603
Study: 11011341

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) adenosine boluses at a dose of 15 to 20 microgram in the right and 18 to 24 microgram in the left coronary artery.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous (IV) adenosine administered as a continuous infusion at a rate of 140 microgram/kg per minute until steady state hyperemia was achieved.
Number of subjects: 52
Study: 8834004

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Intervention and Control
Number of subjects: 5887
Study: 8222668

Group type: EXPERIMENTAL
Intervention: Enucleation (removal of the eye)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation delivered to the tumor by means of a radioactive 'plaque'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 day course of external beam radiation therapy followed by enucleation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0